Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Rodriguez

Clinical Cardiac Electrophysiology Lincoln, RI Medical Doctor

NPI 1427210251 CMS profile 200418

6 Blackstone Valley Pl Ste 105, Ste 105, Lincoln, RI 02865

Open in the dashboard

General payments

$8,534

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Rodriguez of Lincoln, RI is reported in the CMS Open Payments database as having received $8,534 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,862 33
2024 General $731 13
2023 General $605 13
2022 General $1,686 24
2021 General $800 15
2020 General $276 11
2019 General $1,574 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Rodriguez
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to John Rodriguez were reported at $2,862. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year John Rodriguez Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,574 $2,361 $585–$8,260 $163
2020 $276 $993 $247–$4,351 $114
2021 $800 $1,185 $326–$4,739 $132
2022 $1,686 $2,073 $554–$6,789 $149
2023 $605 $2,568 $759–$8,159 $160
2024 $731 $2,557 $703–$7,403 $164
2025 $2,862 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,605 93 payments
  2. Medtronic Vascular, Inc. $868 23 payments
  3. Boston Scientific Corporation $319 3 payments
  4. Janssen Pharmaceuticals, Inc $185 15 payments
  5. E.R. Squibb & Sons, L.L.C. $113 7 payments
  6. Abbott Laboratories $92 6 payments
  7. Novartis Pharmaceuticals Corporation $69 4 payments
  8. Amgen Inc. $53 3 payments
  9. Regeneron Healthcare Solutions, Inc. $51 2 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $41 2 payments
  11. Other $137 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,299 162 payments
  2. Travel and Lodging $1,235 5 payments
Products named General payments · program years 2019–2025
  1. Micra Pacemakers $2,633 31 payments
  2. COBALT DR MRI SURESCAN $802 16 payments
  3. MICRA Pacemakers $444 8 payments
  4. Cobalt $408 5 payments
  5. Advisa $357 12 payments
  6. AZURE XT DR MRI SURESCAN $306 5 payments
  7. Reveal LINQ $273 3 payments
  8. SelectSecure $234 7 payments
  9. XARELTO $185 15 payments
  10. General Therapies $174 1 payment
  11. Other $1,261 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

856

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$164,665

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

33.6%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 149 $111,819
Xarelto Rivaroxaban Brand 34 $30,189
Dofetilide Generic 25 $5,338
Flecainide Acetate Generic 76 $4,425
Quinidine Gluconate Generic 12 $3,970
Amiodarone Hcl Generic 78 $2,226
Metoprolol Succinate Generic 139 $1,795
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 34 $934
Sotalol Sotalol Hcl Brand 41 $934
Midodrine Hcl Generic 11 $522

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$89,700

Medicare's payments for the services billed

Medicare patients

415

Average age 77

Services billed

1,061

202 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 53%
Atrial fibrillation 53%
Heart failure 52%
Chronic kidney disease 45%
Diabetes 41%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record